Rosacea Core Domain Set for Clinical Trials and Practice: A Consensus Statement
- PMID: 38656294
- DOI: 10.1001/jamadermatol.2024.0636
Rosacea Core Domain Set for Clinical Trials and Practice: A Consensus Statement
Abstract
Importance: Inconsistent reporting of outcomes in clinical trials of rosacea is impeding and likely preventing accurate data pooling and meta-analyses. There is a need for standardization of outcomes assessed during intervention trials of rosacea.
Objective: To develop a rosacea core outcome set (COS) based on key domains that are globally relevant and applicable to all demographic groups to be used as a minimum list of outcomes for reporting by rosacea clinical trials, and when appropriate, in clinical practice.
Evidence review: A systematic literature review of rosacea clinical trials was conducted. Discrete outcomes were extracted and augmented through discussions and focus groups with key stakeholders. The initial list of 192 outcomes was refined to identify 50 unique outcomes that were rated through the Delphi process Round 1 by 88 panelists (63 physicians from 17 countries and 25 patients with rosacea in the US) on 9-point Likert scale. Based on feedback, an additional 11 outcomes were added in Round 2. Outcomes deemed to be critical for inclusion (rated 7-9 by ≥70% of both groups) were discussed in consensus meetings. The outcomes deemed to be most important for inclusion by at least 85% of the participants were incorporated into the final core domain set.
Findings: The Delphi process and consensus-building meetings identified a final core set of 8 domains for rosacea clinical trials: ocular signs and symptoms; skin signs of disease; skin symptoms; overall severity; patient satisfaction; quality of life; degree of improvement; and presence and severity of treatment-related adverse events. Recommendations were also made for application in the clinical setting.
Conclusions and relevance: This core domain set for rosacea research is now available; its adoption by researchers may improve the usefulness of future trials of rosacea therapies by enabling meta-analyses and other comparisons across studies. This core domain set may also be useful in clinical practice.
Similar articles
-
Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.Trials. 2016 Sep 1;17(1):429. doi: 10.1186/s13063-016-1554-3. Trials. 2016. PMID: 27580586 Free PMC article.
-
Development of a Core Outcome Set for Clinical Trials in Non-infectious Uveitis of the Posterior Segment.Ophthalmology. 2021 Aug;128(8):1209-1221. doi: 10.1016/j.ophtha.2021.01.022. Epub 2021 Jan 28. Ophthalmology. 2021. PMID: 33515595
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.JAMA Dermatol. 2018 Oct 1;154(10):1137-1144. doi: 10.1001/jamadermatol.2018.1165. JAMA Dermatol. 2018. PMID: 29874367 Free PMC article.
-
A core outcomes set for clinical trials of interventions for young adults with type 1 diabetes: an international, multi-perspective Delphi consensus study.Trials. 2017 Dec 19;18(1):602. doi: 10.1186/s13063-017-2364-y. Trials. 2017. PMID: 29258565 Free PMC article.
Cited by
-
Assessing the uptake of infertility core outcome set in IVF randomized controlled trials.Hum Reprod. 2025 Jan 1;40(1):85-95. doi: 10.1093/humrep/deae255. Hum Reprod. 2025. PMID: 39673431 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
